NEW YORK, March 4 - Celera Genomics, in a move to hasten its metamorphosis as a drug developer, has sold its AgGen animal genomics and genotyping business to MetaMorphix, the companies said on Monday.
MetaMorphix will use the livestock databases to develop new products, according to a statement. The company also gets a subscription to Celera's Discovery System bioinformatics and annotation platform.
In return, Celera has acquired a minority interest in the company and will receive future royalties on new products that MetaMorphix develops by using the database.
The companies did not disclose financial details of the agreement.
MetaMorphix, based in Savage, Md., uses genomics and proteomics to improve livestock and other animals. It focuses on developing products that can accelerate animal growth and speed, and improve meat production, reduce waste, and decrease the use of antibiotics and hormones. The company is also working on products related to population control and behavior in pets.
In December, Celera sold the plant side of its AgGen division to Paradigm in a $2 million stock deal.